WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.
Celltrion Chairman Seo Jung-jin says the South Korean company will spend about $33 billion over a decade on its biologics and pharma businesses.
Takeda releases first post-Shire guidance; Indian generics makers are named in a price-fixing suit; Daiichi's quizartinib fails at FDA.
The price, though a discount from its U.S. sticker, makes Kymriah the most expensive treatment offered on the Japanese public insurance system.
The FDA says Torrent finished product batches were out of spec 340 times in two years, but the company often approved them after retesting.
Takeda sells meds to Novartis and J&J; Daiichi's AZ-shared HER2 antibody-drug conjugate hits key trial goal; Sun scouts for Chinese partner.
Novartis hopes the deal, potentially worth $5.3 billion, could better position itself in front-of-the-eye therapies.
AZ warns of slower China growth; BeiGene chief ranks among highest-paid biopharma CEOs; Kangmei faces delisting over huge accounting "error."
Keytruda grew sales by 60% at constant currencies, boosting its share in Merck's portfolio. Could China and a few new indications step on the gas?
BeiGene CEO John Oyler's $27.9 million pay in 2018 surpassed many Big Pharma and Big Biotech pay packages, but it's likely a one-time thing.